Skip to main content
Evidence Snapshot

Serine/threonine-protein kinase pim-1

CHEMBL2147 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T23:51:41Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2147
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Serine/threonine-protein kinase pim-1 as ChEMBL target CHEMBL2147, mapped to UniProt P11309. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Serine/threonine-protein kinase pim-1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2147
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P11309
Serine/threonine-protein kinase pim-1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Serine/threonine-protein kinase pim-1 matters

As of 2026-09-13

Serine/threonine-protein kinase pim-1 is reviewed as Serine/threonine-protein kinase pim-1 (UniProt P11309); the current evidence base includes 9 approved drugs, 8594 compounds, and 974 assays, with lead potency reaching pChEMBL 11.0.

Protein context
Serine/threonine-protein kinase pim-1

Serine/threonine-protein kinase pim-1 Sequence length is 313 aa.

Review this target as Serine/threonine-protein kinase pim-1, mapped to UniProt P11309. Sequence length is 313 aa.

Protein source · UniProt accession via ChEMBL component mapping
UniProt P11309 Protein
Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 9 approved drugs, 8594 compounds, and 974 assays for this target. The dominant activity type is IC50. CHEMBL3318854 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL3318854 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
9 approved pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Serine/threonine-protein kinase pim-1 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P11309, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

8594
Total Compounds
974
Total Assays
9
Approved Drugs
IC50: 6685.0, KI: 3939.0, EC50: 46.0, KD: 431.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL3318854
 11.0 Ki —
No preferred name
CHEMBL3634783
 11.0 Ki —
No preferred name
CHEMBL3648671
 11.0 Ki —
No preferred name
CHEMBL3648682
 11.0 Ki —
No preferred name
CHEMBL3648693
 11.0 Ki —

Approved Drugs

Structure Compound First Approval
ABEMACICLIB
CHEMBL3301610
 2017
MIDOSTAURIN
CHEMBL608533
 2017
MITOXANTRONE HYDROCHLORIDE
CHEMBL1417019
 1987
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T23:51:41Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2147